Home

EXOSOMES

Harnessing the

Power of Evolution

organicell™REGENERATIVE MEDICINE

COVID-19 STATEMENT

Organicell™ has recently received an approval notification from the FDA for its investigational new drug (IND) application investigating their lead product, Organicell™ Flow, for patients diagnosed with moderate to severe acute respiratory syndrome (SARS) due to COVID-19 infection. This trial will be the first randomized, double-blinded, placebo-controlled, phase I/II multi-center clinical trial investigating the safety and potential efficacy of perinatal sourced components for COVID-19.

Organicell™ is the leading, fully integrated Regenerative Medicine Company. Our world class research, technology, manufacturing, and clinical development team is focused on creating new regenerative medicine.

We believe that our ground-breaking research in the field of nanotechnology, specifically extracellular vesicles and perinatal-derived nanoparticles, is the next frontier of regenerative therapeutics. Organicell™ is committed to creating life changing and lifesaving therapies for patients.

The Next Generation of

Biologic Medicine

Organicell™ is the leading, fully integrated Biologic Medicine Company. Our world class research, technology, manufacturing and clinical development team is focused on creating new biologic medicine.

We believe that our ground-breaking research in the field of nanotechnology, specifically extracellular vesicles and perinatal-derived nanoparticles, is the next frontier of cell-based regenerative therapeutics. Organicell™ is committed to creating life changing and lifesaving therapies for patients.